Federal Register
Notices > Importers >
Sigma Aldrich Manufacturing LLC
FR Doc E6-13727 [Federal Register: August 21, 2006 (Volume 71, Number 161)]
[Notices] [Page 48556-48557] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21au06-72]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a
registration under this Section to a bulk manufacturer of a controlled substance
in Schedule I or II and prior to issuing a regulation under 21
U.S.C. 952(a)
authorizing the importation of such a substance, provide manufacturers holding
registrations for the bulk manufacture of the substance an opportunity for a
hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
January 20, 2006, Sigma Aldrich Manufacturing LLC., Subsidiary of Sigma-Aldrich
Company, 3500 Dekalb Street, St. Louis, Missouri 63118, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered as an
importer of the basic classes of controlled substances listed in Schedule I and
II:
Drug
|
Schedule
|
Cathinone (1235)
|
I
|
Methcathinone (1237)
|
I
|
Aminorex (1585)
|
I
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
Methaqualone (2565)
|
I
|
Ibogaine (7260)
|
I
|
Lysergic acid diethylamide (7315)
|
I
|
Marihuana (7360)
|
I
|
Tetrahydrocannabinols (7370)
|
I
|
Mescaline (7381)
|
I
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
3,4-Methylenedioxymethamphetamine (MDMA) (7405)
|
I
|
4-Methoxyamphetamine (7411)
|
I
|
Bufotenine (7433)
|
I
|
Diethyltryptamine (7434)
|
I
|
Dimethyltryptamine (7435)
|
I
|
Psilocybin (7437)
|
I
|
Psilocyn (7438)
|
I
|
N-Ethyl-1-phenylcyclohexylamine (7455)
|
I
|
N-Benzylpiperazine (BZP) (7493)
|
I
|
Trifluoromethylphenyl Piperazine (7494)
|
I
|
Heroin (9200)
|
I
|
Normorphine (9313)
|
I
|
Etonitazene (9624)
|
I
|
Amphetamine (1100)
|
II
|
Methamphetamine (1105)
|
II
|
Methylphenidate (1724)
|
II
|
Amobarbital (2125)
|
II
|
Pentobarbital (2270)
|
II
|
Secobarbital (2315)
|
II
|
Glutethimide (2550)
|
II
|
Nabilone (7379)
|
II
|
Phencyclidine (7471)
|
II
|
Cocaine (9041)
|
II
|
Codeine (9050)
|
II
|
Diprenorphine (9058)
|
II
|
Oxycodone (9143)
|
II
|
Hydromorphone (9150)
|
II
|
Diphenoxylate (9170)
|
II
|
Ecgonine (9180)
|
II
|
Ethylmorphine (9190)
|
II
|
Hydrocodone (9193)
|
II
|
Levorphanol (9220)
|
II
|
Meperidine (9230)
|
II
|
Methadone (9250)
|
II
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
Morphine (9300)
|
II
|
Thebaine (9333)
|
II
|
Opium powdered (9639)
|
II
|
Oxymorphone (9652)
|
II
|
Fentanyl (9801)
|
II
|
The company plans to import the listed controlled substances for sale to
research facilities for drug testing and analysis.
Any manufacturer who is presently, or is applying to be, registered with DEA
to manufacture such basic classes of controlled substances may file comments or
objections to the issuance of the proposed registration and may, at the same
time, file a written request for a hearing on such application pursuant to 21
CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative/ODL; or any being sent via
express mail should
[[Page 48557]]
be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL,
2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no
later than September 20, 2006.
This procedure is to be conducted simultaneously with and independent of the
procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a
previous notice published in the Federal Register on September 23, 1975, (40 FR
43745-46), all applicants for registration to import a basic class of any
controlled substance listed in Schedule I or II are, and will continue to be
required to demonstrate to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21
U.S.C. 823(a), and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: August 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration.
[FR Doc. E6-13727 Filed 8-18-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|